Goldman Sachs’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $111M | Buy |
298,841
+83,892
| +39% | +$25.1M | 0.01% | 1149 |
|
|
2026
Q1 | $55.5M | Sell |
214,949
-78,576
| -27% | -$20.9M | 0.01% | 1495 |
|
|
2025
Q4 | $72.4M | Sell |
293,525
-54,725
| -16% | -$11.5M | 0.01% | 1214 |
|
|
2025
Q3 | $61.5M | Sell |
348,250
-182,111
| -34% | -$27.3M | 0.01% | 1271 |
|
|
2025
Q2 | $72.9M | Buy |
530,361
+296,721
| +127% | +$43.6M | 0.01% | 1089 |
|
|
2025
Q1 | $42.1M | Sell |
233,640
-43,535
| -16% | -$7.32M | 0.01% | 1344 |
|
|
2024
Q4 | $43.4M | Sell |
277,175
-24,179
| -8% | -$4.29M | 0.01% | 1425 |
|
|
2024
Q3 | $54.9M | Sell |
301,354
-120,977
| -29% | -$23.3M | 0.01% | 1175 |
|
|
2024
Q2 | $77.6M | Sell |
422,331
-12,243
| -3% | -$2.06M | 0.01% | 916 |
|
|
2024
Q1 | $77.3M | Buy |
434,574
+206,521
| +91% | +$28.7M | 0.01% | 918 |
|
|
2023
Q4 | $28.3M | Buy |
228,053
+43,709
| +24% | +$4.85M | 0.01% | 1599 |
|
|
2023
Q3 | $21.4M | Sell |
184,344
-10,592
| -5% | -$1.29M | ﹤0.01% | 1744 |
|
|
2023
Q2 | $22.9M | Sell |
194,936
-62,924
| -24% | -$6.42M | ﹤0.01% | 1728 |
|
|
2023
Q1 | $20.6M | Buy |
257,860
+110,259
| +75% | +$8.66M | ﹤0.01% | 1797 |
|
|
2022
Q4 | $11.7M | Buy |
147,601
+5,216
| +4% | +$387K | ﹤0.01% | 2439 |
|
|
2022
Q3 | $9.92M | Sell |
142,385
-21,359
| -13% | -$1.54M | ﹤0.01% | 2507 |
|
|
2022
Q2 | $10.8M | Buy |
163,744
+27,697
| +20% | +$1.72M | ﹤0.01% | 2449 |
|
|
2022
Q1 | $9.05M | Buy |
136,047
+82,894
| +156% | +$5.17M | ﹤0.01% | 2792 |
|
|
2021
Q4 | $3.72M | Buy |
53,153
+31,828
| +149% | +$1.85M | ﹤0.01% | 3704 |
|
|
2021
Q3 | $1.11M | Sell |
21,325
-114,533
| -84% | -$6.78M | ﹤0.01% | 4658 |
|
|
2021
Q2 | $9.24M | Sell |
135,858
-46,624
| -26% | -$3.25M | ﹤0.01% | 2762 |
|
|
2021
Q1 | $14.1M | Sell |
182,482
-32,802
| -15% | -$2.38M | ﹤0.01% | 2253 |
|
|
2020
Q4 | $12.9M | Sell |
215,284
-59,858
| -22% | -$2.99M | ﹤0.01% | 2242 |
|
|
2020
Q3 | $11.8M | Sell |
275,142
-9,254
| -3% | -$402K | ﹤0.01% | 2168 |
|
|
2020
Q2 | $11.8M | Buy |
284,396
+183,632
| +182% | +$8.83M | ﹤0.01% | 2140 |
|
|
2020
Q1 | $4.36M | Buy |
100,764
+20,832
| +26% | +$1.09M | ﹤0.01% | 2749 |
|
|
2019
Q4 | $4.43M | Buy |
+79,932
| New | +$3.92M | ﹤0.01% | 3054 |
|
|
2019
Q3 | – | Sell |
-8,184
| Closed | -$330K | – | 5287 |
|
|
2019
Q2 | $330K | Sell |
8,184
-23,100
| -74% | -$755K | ﹤0.01% | 4580 |
|
|
2019
Q1 | $1.03M | Buy |
+31,284
| New | +$737K | ﹤0.01% | 4036 |
|
|
2018
Q1 | – | Sell |
-22,036
| Closed | -$232K | – | 6166 |
|
|
2017
Q4 | $232K | Buy |
22,036
+2,236
| +11% | +$22.4K | ﹤0.01% | 5337 |
|
|
2017
Q3 | $197K | Buy |
+19,800
| New | +$200K | ﹤0.01% | 5762 |
|
Other funds holding KRYS
ACA
SCM
Goldman Sachs's KRYS Position: Q2 2026 in Review
Goldman Sachs increased its Krystal Biotech (KRYS) stake by 39% in Q2 2026, buying an estimated $25.1M and bringing the position to 298,841 shares worth $111M. The position accounts for 0.01% of the portfolio, ranked #1149.
Goldman Sachs first reported a position in KRYS in Q3 2017 and has held it in 31 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.
- Goldman Sachs held 298,841 shares of Krystal Biotech worth $111M as of Q2 2026.
- Goldman Sachs bought 83,892 Krystal Biotech shares in Q2 2026, an estimated $25.1M.
- Krystal Biotech made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1149 holding.
- Goldman Sachs first reported a position in Krystal Biotech in Q3 2017 and has held it in 31 quarters since.
- 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.